A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).

NCT05507229 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholera

Interventions

BIOLOGICAL: Hillchol vaccine
BIOLOGICAL: Shanchol Vaccine

Sponsor

Bharat Biotech International Limited